Skip to main content
Get the Weekly ESG Brief

Haemonetics Corporation

HAENYSETrackedMarket Data VerifiedHealth CareHealth Care Supplies

Coverage
Coverage universe Identity published; no third-party ESG observation yet.
ESG profile reviewed
Last editorial update to this profile.
Quote
Delayed quoteObservation time is shown beside the price.
Methodology
How we rateProvider ratings are shown separately, never blended.

Market overview

USD 105.46

Down−USD 0.33 (−0.31%) Day change

Delayed quote · As of · USD · Market data via Massive Stock Widgets

This quote can lag the exchange by several minutes. It is not a real-time price.

Open
USD 104.99
Previous close
USD 105.79
Day high
USD 106.50
Day low
USD 105.46
Volume
36,195
Market cap
USD 4,798,118,912
Price chart · 1 Year
Haemonetics Corporation 1 Year price chartHaemonetics Corporation, nyse:HAE, 1 Year price chart in USD. Start USD 48.17, end USD 105.30, high USD 108.80, low USD 48.12, up.
Period1 YearFirst closeUSD 48.17Last closeUSD 105.30Maximum closeUSD 108.80Minimum closeUSD 48.12Period change+USD 57.13Period percentage change+118.60%Chart as ofSep 25, 2026, 1:30 PM GMT+0000
View Chart Data
Representative chart points — 24 of 251
Date and time Open High Low Close Volume
USD 47.76 USD 48.29 USD 47.32 USD 48.17 932,200
USD 48.42 USD 48.46 USD 47.79 USD 48.12 752,400
USD 71.56 USD 74.19 USD 71.48 USD 73.12 1,163,700
USD 80.13 USD 80.86 USD 79.65 USD 80.75 611,700
USD 83.84 USD 84.51 USD 82.07 USD 83.49 949,500
USD 80.27 USD 81.19 USD 80.03 USD 80.98 360,600
USD 75.51 USD 76.11 USD 73.36 USD 74.00 1,103,300
USD 66.73 USD 66.85 USD 65.32 USD 65.78 800,900
USD 58.71 USD 60.78 USD 58.43 USD 60.63 940,600
USD 64.31 USD 65.10 USD 63.60 USD 64.23 694,400
USD 58.74 USD 59.14 USD 57.96 USD 58.58 1,260,700
USD 56.61 USD 58.50 USD 56.61 USD 58.46 470,700
USD 61.29 USD 61.83 USD 59.83 USD 60.21 589,300
USD 55.93 USD 56.74 USD 52.50 USD 52.67 1,273,800
USD 58.91 USD 61.94 USD 57.73 USD 61.94 1,182,500
USD 71.45 USD 75.70 USD 70.66 USD 74.88 1,343,200
USD 73.60 USD 74.98 USD 72.29 USD 72.87 523,900
USD 75.23 USD 76.58 USD 74.67 USD 76.19 456,300
USD 79.35 USD 80.72 USD 79.35 USD 79.91 803,200
USD 87.39 USD 87.97 USD 85.97 USD 86.61 571,100
USD 109.24 USD 109.57 USD 107.00 USD 108.80 582,100
USD 108.13 USD 108.68 USD 106.84 USD 108.32 502,200
USD 102.02 USD 102.95 USD 100.60 USD 101.06 602,300
USD 105.72 USD 106.58 USD 104.71 USD 105.30 492,600

Company Profile & Business Model Overview

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital’s blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Sustainability Strengths & Catalysts (Pros)

  • Product focus on blood and plasma collection and transfusion management supports critical healthcare infrastructure and patient care, aligning the business with essential public health services.
  • Haemonetics publishes corporate responsibility information and frames its purpose around advancing patient care and stakeholder trust, indicating institutional attention to ESG-related governance and stakeholder engagement.
  • The company’s diversified product portfolio across plasma, blood center and hospital segments can enhance operational resilience and reduce concentration-related supply risks for healthcare customers.

Material Risks & Governance Concerns (Cons)

  • Haemonetics operates in regulated medical-device and blood-plasma sectors where product safety, quality control and regulatory compliance failures could lead to material patient-safety incidents, recalls or litigation risk.
  • Manufacturing and global supply-chain operations for medical disposables and devices expose the company to environmental impacts (e.g., waste from single-use disposables) and to supply-chain labor and sourcing risks across multiple jurisdictions.

Related ESG Peer Equities

Companies in Health Care evaluated across carbon intensity, social metrics, and board governance.

Explore Health Care Peers →

ESG & Sustainability Rating Breakdown

Synthesized multi-provider rating across Environmental, Social, and Corporate Governance dimensions.

Audited Methodology

Coverage PendingThird-Party ESG Coverage Under Review

Formal published scorecards from MSCI ESG Research and Sustainalytics are not currently available for this ticker. The Impact Investor tracks corporate sustainability disclosures, SEC 10-K filings, and governance releases.

Data integrity and methodology

MSCI and Sustainalytics ratings are shown separately with their own observation dates; they are not blended into one score, and providers can disagree. Market quotes are delayed or last-close values, and every snapshot states its source and observation time. Read the full rating methodology.

FAQ

Frequently Asked Questions

Direct answers on sustainability scores, risk methodologies, and peer rankings.

What is Haemonetics Corporation (HAE)'s ESG rating and sustainability score?

Formal published scorecards from MSCI and Sustainalytics are under ongoing review for Haemonetics Corporation (HAE). The Impact Investor tracks corporate sustainability disclosures, SEC 10-K filings, and governance releases.

Is Haemonetics Corporation considered an ESG leader or laggard in Health Care?

Independent benchmark status for Haemonetics Corporation is evaluated relative to Health Care peers once third-party coverage publishes official methodology scores.

What are the main ESG risks and controversies for Haemonetics Corporation?

Key material risks for Haemonetics Corporation include: Haemonetics operates in regulated medical-device and blood-plasma sectors where product safety, quality control and regulatory compliance failures could lead to material patient-safety incidents, recalls or litigation risk.; Manufacturing and global supply-chain operations for medical disposables and devices expose the company to environmental impacts (e.g., waste from single-use disposables) and to supply-chain labor and sourcing risks across multiple jurisdictions.. Investors should evaluate whether corporate mitigation plans adequately address these vulnerabilities.

How does The Impact Investor evaluate ESG stock profiles?

The Impact Investor presents audited third-party ratings from MSCI and Sustainalytics alongside delayed market data and financial fundamentals. We do not blend ratings into proprietary black-box scores, and ratings are never modified by advertising or affiliate relationships.